Inhibition of NHE3-mediated sodium absorption in the gut reduced cardiac end-organ damage without deteriorating renal function in obese spontaneously hypertensive rats

Journal of Cardiovascular Pharmacology

Volumn 67, Issue 3, 2016, Pages 225-231

  Linz, Benedikt ^a   Hohl, Mathias ^a   Reil, Jan Christian ^a   Böhm, Michael ^a   Linz, Dominik ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

blood pressure; cardiac remodeling; intestinal sodium absorption; NHE3 inhibition

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; COLLAGEN TYPE 1; COLLAGEN TYPE 3; PLACEBO; PROTEIN INHIBITOR; SODIUM CHLORIDE COTRANSPORTER; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM PROTON EXCHANGE PROTEIN 3; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; [1 (BETA DEXTRO GLUCOPYRANOSYL) 3 [3 [ 6,8 DICHLORO 2 METHYL 1,2,3,4 TETRAHYDROISO CHINOLIN 4 YL]PHENYL]UREA]; ANTIHYPERTENSIVE AGENT; SODIUM; SODIUM PROTON EXCHANGE PROTEIN; SODIUM-HYDROGEN EXCHANGER 3; UREA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMICAL ANALYSIS; CONTROLLED STUDY; GENE EXPRESSION; GLOMERULUS FILTRATION RATE; HEART INJURY; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE MASS; HEART MUSCLE CELL; HISTOPATHOLOGY; IC50; INTESTINE; KIDNEY FUNCTION; KIDNEY INJURY; KOLETSKY RAT; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SODIUM ABSORPTION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; CARDIAC MUSCLE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; GENETIC PREDISPOSITION; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE REMODELING; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INTESTINE ABSORPTION; KIDNEY; KIDNEY DISEASES; METABOLISM; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PREVENTION AND CONTROL; SPONTANEOUSLY HYPERTENSIVE RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INTESTINAL ABSORPTION; INTESTINES; KIDNEY; KIDNEY DISEASES; MALE; MYOCARDIUM; OBESITY; PHENOTYPE; RATS, INBRED SHR; SODIUM; SODIUM-HYDROGEN ANTIPORTER; STROKE VOLUME; UREA; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 84962495928     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000336     Document Type: Article

References (23)

1. Ezzati M, Lopez AD, Vander Hoorn S, et al; Comparative Risk Assessment Collaborating Group. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360:1347-1360.
2. Reuter S, Bössemaker E, Hausberg M, et al. Effect of excessive salt intake: role of plasma sodium. Curr Hypertens Rep. 2009;11:91-97.
3. Meneton P, Jeunemaitre X, de Wardener HE, et al. Links between dietary salt intake, renal salt handling, blood pressure, and cardiovascular diseases. Physiol Rev. 2005;85:679-715.
4. O'Donnell M, Mente A, Rangarajan S, et al; PURE Investigators. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med. 2014;371:612-623.
5. Bibbins-Domingo K, Chertow GM, Coxson PG, et al. Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med. 2010;263:590-599.
6. O'Donnell MJ, Yusuf S, Mente A, et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA. 2011;306: 2229-2238.
7. Felker GM, O'Connor CM, Braunwald E. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail. 2009;2:56-62.
8. Bradford EM, Sartor MA, Gawenis LR, et al. Reduced NHE3-mediated Na+ absorption increases survival and decreases the incidence of intestinal obstructions in cystic fibrosis mice. Am J Physiol Gastrointest Liver Physiol. 2009;296:G886-G898.
9. He P, Yun CC. Mechanism of the regulation of the intestinal Na/H exchanger NHE3. J Biomed Biotechnol. 2010;2010:238080.
10. Klisic J, Hu MC, Nief V, et al. Insulin activates Na(+)/H(+) exchanger 3: biphasic response and glucocorticoid dependence. Am J Physiol Renal Physiol. 2002;283:F532-F539.
11. Horita S, Seki G, Yamada H, et al. Insulin resistance, obesity, hypertension, and renal sodium transport. Int J Hypertens. 2011;2011:391762.
12. Linz D, Wirth K, Linz W, et al. Antihypertensive and laxative effects by pharmacological inhibition of sodium-proton-exchanger subtype 3-mediated sodium absorption in the gut. Hypertension. 2012;60:1560-1567.
13. Spencer AG, Labonte ED, Rosenbaum DP, et al. Intestinal inhibition of the Na+/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med. 2014;6:227ra36.
14. Ernsberger P, Koletsky RJ, Friedman JE: Molecular pathology in the obese spontaneous hypertensive koletsky rat: A model of syndrome X. Ann N Y Acad Sci. 1999;892:272-288.
15. Linz D, Hohl M, Mahfoud F, et al. Cardiac remodeling and myocardial dysfunction in obese spontaneously hypertensive rats. J Transl Med. 2012;10:187.
16. Linz D, Hohl M, Schötze J, et al. Progression of kidney injury and cardiac remodeling in obese spontaneously hypertensive rats: The role of renal sympathetic innervation. Am J Hypertens. 2015;28:256-265.
17. Lee VS, Rusinek H, Bokacheva L, et al. Renal function measurements from MR renography and a simplified multicompartmental model. Am J Physiol Renal Physiol. 2007;292:F1548-F1559.
18. Xu C, Arinze IJ, Johnson J, et al. Metabolic dysregulation in the SHROB rat reflects abnormal expression of transcription factors and enzymes that regulate carbohydrate metabolism. J Nutr Biochem. 2008;19:305-312.
19. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34:2159-2219.
20. McMurray JJ, Adamopoulos S, Anker SD, et al; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787-1847.
21. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005;45:S1-S153.
22. Metra M, Bugatti S, Bettari L, et al. Can we improve the treatment of congestion in heart failure? Expert Opin. 2011;12:1369-1379.
23. Sanchez MI, Bercik P. Epidemiology and burden of chronic constipation. Can J Gastroenterol. 2011;25(suppl B):11B-15B.